CXCR4 and cholangiocarcinoma: Xie et al. developed cholesterol-modified polymeric C-X-C receptor type 4 (CXCR4) antagonist (PCX) nanoparticles, with codelivery of anti-miR-210 to cooperatively exert antitumor activity in CCA [137].